Despite advances in antimicrobial therapy and medical support, septic shock remains a leading cause of death. Emerging adjunctive therapy for septic shock can be divided into those directed against bacterial components, those directed against host-derived inflammatory mediators and those designed to limit tissue damage. All trials of new adjunctive therapies for sepsis and septic shock conducted to date have failed to show efficacy. Therapies against endotoxin, tumour necrosis factor, interleukin-1 and platelet activating factor did not reduce mortality. Future effective therapies will probably use combination of agents depending upon the nature of the infection and the type of patient.
Septic shock remains a major cause of morbidity and mortality among hospitalised patients despite advances in antimicrobial therapy and medical support.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.